CDPH ASP Toolkit 2015

Example 5.3 Sutter Eden Medical Center Antibiogram 2014



Sutter Health Shared Laboratory 2950 Collier Canyon Rd. Livermore CA 94551

Eden Medical Center

1 January-31 December 2014 Cumulative Antimicrobial Susceptibility Report*
Percent Susceptible

Gram Negative Organisms	No. Strains	ESBL	Ampicillin	Ampicillin/Sulbactam	Cefazolin	Cefoxitin	Ceftazidime	Ceftriaxone	Cefepime	Ciprofloxacin	Ertapenem	Gentamicin	Imipenem	Levofloxacin	Nitrofurantoin**	Piperacillin/Tazobactam	Trimethoprim/Sulfa
Citrobacter freundii	31	4355	4355	## #	445e	2 78	81%	81%	100%	94%	100%	94%	97%	97%	93%	5 78	81%
Enterobacter cloacae	54	9336	9550	3050	1850	25 28	72%	71%	98%	96%	91%	96%	96%	96%	35%	81%	88%
Escherichia cali	1495	10%	49%	59%	43%	86%	94%	90%	97%	72%	99%	90%	100%	72%	94%	95%	73%
Klebsiella oxytoca	35	3%	#38E/6	62%	8%	97%	97%	97%	100%	97%	100%	97%	100%	97%	87%	97%	88%
Klebsiella pneumoniae	258	12%	#1826	78%	46%	93%	90%	89%	97%	88%	97%	95%	98%	88%	33%	89%	86%
Morganella species	42	9330	9390	2%	3356	43%	79%	74%	95%	48%	100%	76%	05 75	51%	65 7.8	95%	48%
Proteus mirabilis	230	USE (C	65%	78%	15%	86%	94%	83%	94%	53%	100%	77%	w 78	57%	0 78	100%	59%
Providencia species	36	U.S.	23326	1135	1336	94%	88%	85%	97%	24%	93%	05 78	85 7S	24%	65 78	94%	61%
Ps eudomona s a eruginosa	204	UNE (c	#1856	456	1115 E	28	87%	05 7.8	92%	62%	65 78	88%	85%	58%	0 78	87%	s 7s

Note: CLSI recommends that to obtain a reasonable statistical estimate of cumulative %S rates, it is desirable to include only species with testing data for >= 30 isolates.

⁽⁻⁾ drug not tested or drug not indicated

Acinetobacter baumanii complext	18	30 2 00	www.	#15 <u>5</u> 6	82%	E 78	97 9	37%	0 78	53%	4 2%	05 73	58%	84%	42%	: 78	5 78	53%
Stenotrophomonas maltophilia†	17	U.S. 6	U.V.E.V.	1115	1111E	± 78	u 7s	0 70	U 78	w 7s	to 78 a	0 7S	0 7S	U 78	81%	: 7s	5 78	100%

† Fewer than 30 isolates indicates less statistical validity of the estimates of % S. Interpret with caution.

Gram Positive Organisms	No.5trains	Ampicillin	Cefazolin	Erythromycin	Linezolid	Levofloxacin	Nitrofurantoin	Clindamycin	Oxacillin	Pencillin	Tetracycline	Trimethoprim/Sulfa	Vancomycin
Enterococcus fa ecalis	37	97%	(Nati	3848	100%	57%	100%	45	40	97%	24%	40	81%
Enterococcus faecium	35	8%	X 2 3	(vais	100%	3%	10%	98	93	8%	17%	93	11%
Enterococcus NOS	173	95%	(V a)3	JY a ls	100%	74%	98%	93	93	96%	21%	93	99%
Methicillin resistant Staphylococcus aureus (MRSA)	158	JX=33	7000	12%	999	21%	95%	58%	93	93	92%	99%	100%
Staphylococcus aureus (MSSA)	237	973	100%	68%	25.0	79%	100%	83%	99%	45	94%	99%	100%

+For Staphylococus aureus, 42% of all isolates reported an MIC of \leftarrow 0.5 and 57% reported an MIC of 1.

POTENTIAL PROPERTY AND ADDRESS OF THE POTENTIAL PROPERTY ADDRESS OF THE POTENTIAL	1961	477	477	(7)		27/2		200	0.0	200	0.0	257	253
Streptococcus pneumoniae†	8	(Kass	(Ma)	75%	3(9)3	100%	10 3 15	100%	98	88%	93	93	100%
500 - 200	135										_		777

MIC's performed only on sterile site isolates and those that are penicillin screen resisitant.

For more info about this example contact Jeffrey Silvers, MD at Silverj@sutterhealth.org

^{* %}S for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

^{**}Nitrofurantoin, data from testing urine isolates only

[†] Fewer than 30 isolates indicates less statistical validity of the estimates of % S. Interpret with caution.